94 results about "Argatroban" patented technology

The invention relates to a method for synthesizing argatroban. The method comprises the following steps that nitryl L-arginie and quinoline sulfonchloride are condensed, and undergo amidation with piperidine ethyl formate, followed by hydrolysis and hydrogenation to obtain argatroban; the amidation is to make carboxylate (c-v) and (2R, 4R) 4MPE (Z-VII) react in an organic solvent in the presence of condensing agent, or the presence of both condensing agent and dehydration promoter, in which the molecular ratio of carboxylate (c-v): (2R, 4R) 4MPE (Z-VII): condensing agent: dehydration promoter is 1: 0.8-1.2: 0.8-1.2: 0-1.2. The condensing agent adopted by the invention is diphenylphosphoryl azide, diethylthiophosphoryl, chlorophosphoric acid diethyl or bromophosphoric acid diethyl. The invention has simplified operation, lowered cost, decreased pollution, increased yielding rate, and is suitable for large-scale industrialized production of argatroban.

The invention relates to a method of treatment of resistance to platelet inhibitors, i.e. a method to overcome resistance of treatment with platelet inhibitors, said method comprising administering a therapeutically effective amount of dipyridamole in combination with a platelet inhibitor and, optionally, in combination with a third antithrombotic component such as direct thrombin inhibitors, factor Xa inhibitors, combined thrombin/factor Xa inhibitors, heparin, low molecular weight heparin, argatroban, bivalrudin, hirulog or polyglycans to a patient in need thereof. The invention further relates to the use of dipyridamole for the manufacture of a pharmaceutical composition for treatment of resistance to platelet inhibitors. The invention also relates to a method to diagnose resistance to treatment with platelet inhibitors, said method comprising measurement of the density of binding of Annexin V on platelets.

The invention provides an aqueous formulation of argatroban and of related compounds along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo- saccharides. An especially preferred embodiment is a ready-to-use 1 mg/ml injectable dosage form having argatroban, lactobionic acid, and methionine.

The invention relates to a method for preparing N<2>-(3-methyl-8-quinoline sulfonyl)- N-nitryl-L-arginine as the intermediate of argatroban. The method comprises the following steps that the reaction of N-nitryl-L-arginine and a 3-methyl-8-quinoline sulfonyl chloride-THF solution is carried out in an aqueous solution of sodium carbonate ; after the reaction ends, THP is collected through evaporation, and the water layer is extracted with an organic solvent, then THF is added with pH adjusted to 2-3, and then a solid saturated water layer of inorganic salt is added; THF is separated and a desiccant is added and stirred for 10-24 hours, with water content of THF measured to be less than 1 percent, then a molecular sift is added for drying, with the water content of THF controlled within 0.2 percent, and then THF reacts with (2R, 4R) 4MPE directly. The invention solves well the control on the water content of N<2>-(3-methyl-8 quinoline sulfonyl)-N N-nitryl-L-arginine, ensures the successful implementation of amide acylation, and satisfies the requirement of the large-scale industrial production.

The invention discloses an Argatroban liposome injection and a preparation method thereof. The Argatroban liposome injection with excellent quality is prepared by selecting Argatroban, sphingomyelin, octadecylamine, and tween 80 according to specific proportion. Compared with preparations in the prior art, the injection disclosed herein has improved stability and bioavailability, improved qualityof the preparation products, reduced toxic and side effect, stable drug release, and remarkable curative effect.

The invention discloses a blood purification membrane with an anticoagulant property and a preparation method thereof. The blood purification membrane comprises a matrix, a polydopamine layer attachedto the surface of the substrate, argatroban grafted on the polydopamine layer and glutathione. The whole surface modification process is simple in experimental conditions, has strong controllability,and is economical and environmentally-friendly; the high-efficiency anti-coagulation on the local part of a material is realized; the blood coagulation system of a body is not affected; the blood compatibility is significantly improved; and the grafted anticoagulant drug argatroban has no antigenicity and does not cause heparin-induced thrombocytopenia.

The invention discloses a method for synthesizing argatroban. The method comprises the following steps: the (2R, 4R)-N-Fmoc-4-methyl-2-nipecotic acid reacts with high polymer resin to obtain (2R, 4R)-N-Fmoc-4-methyl-2-nipecotic acid-resin; deprotection is carried out, Fmoc-arginyl (nitryl)-OH is coupled by a solid phase synthesis method to obtain Fmoc-arginyl (nitryl)-(2R, 4R)-4-methyl-2-nipecotic acid-resin; the deprotection is carried out again, the 3-methyl-8-quinolinesulfonyl chloride is coupled by the solid phase synthesis method to obtain 3-methyl-8-quinolinesulfonyl-arginyl (nitryl)-(2R, 4R)-4-methyl-2-nipecotic acid-resin; cracking cutting reaction is performed to the obtained resin to obtain 3-methyl-8-quinolinesulfonyl-arginyl (nitryl)-(2R, 4R)-4-methyl-2-nipecotic acid; the argatroban crude product is obtained through catalytic hydrogenation; and the argatroban is obtained through recrystallization. The method is suitable for the large-scale production and is simple and easy in operation, stable in process and low in production cost, and the total yield is up to 60 percent.

The invention discloses a preparing method of Argatroban hydrate, which comprises the following steps: refluxing Argatroban and water for 0.5-1.0h; dissolving; cooling to indoor temperature; evolving white crystal; filtering; washing twice; drying to obtain medical Argatroban hydrate. The invention guarantees the constant rate of R and S without other organic impurity, which improves hydrating receiving rate between 90% and 95%.

A drug releasing medical device of the invention is provided with a controlled drug release composition containing 100 parts by weight of an organic polymeric material which is soluble in an organic solvent and insoluble in water, 5 to 60 parts by weight of a release auxiliary agent which is lipid-soluble and low in molecular weight and a 1 to 70 parts by weight of a drug. When the composition is applied to a stent, a catheter, an organ replacement medical device, an artificial organ or the like in the form of coating or the like, a drug releasing function is given to the medical device. From a surface of a stent for treating coronary stenosis, which is a preferred embodiment, argatroban, sarpogrelate hydrochloride or both of them are released gradually. In order to express a controlled release property in a desired period of time, the drug to be released gradually is carried in a polymeric material coated on a metal surface constituting the stent or in a porous stent substrate. It is preferred that the polymeric material is noncrystalline and further biodegradable and contains a tartaric acid ester, a malic acid ester or a monoester or diester of glycerine as the release auxiliary agent.

The invention discloses an anticoagulation PVDF flat separation film, also discloses a making method of the anticoagulation PVDF flat separation film, and belongs to the technical field of films. The making method of the anticoagulation PVDF flat separation film comprises the following steps: 1, preparing a polyacrylic acid grafted polyvinylidene fluoride copolymer PVDF-g-PAA; 2, making a PVDF-g-PAA flat separation film; and 3, making an argatroban grafted and modified PVDF-ARG film. A PVDF film is modified by micro-molecular argatroban with a high efficiency anticoagulation effect with acrylic acid as a medium in order to obtain a PVDF separation film material with a good anticoagulation effect. The anticoagulation PVDF flat separation film can obviously prolong the recalcification time of the film, substantially reduces adhesion of platelet erythrocytes on the surface of the film, reduces the hemolysis rate, improves the anticoagulation performance and greatly improves the blood compatibility. The method has the characteristics of simple process and easy industrialization enforcement.

An aqueous, stable, sterile pharmaceutical composition of the thrombin inhibitor argatroban in a solution containing an acid to solubilize the argatroban, substantially free from dehydrated alcohol is described, as well as a method for its preparation.

The invention provides an argatroban drug composition. Argatroban is used as a main drug, and auxiliary solution consisting of anhydrous ethanol, propylene glycol and water is used as dissolving liquid, so that the argatroban drug composition is prepared. The weight ratio of the argatroban, the anhydrous ethanol and the propylene glycol is 1:(20-50):(40-80). The pH (potential of hydrogen) values of the obtained composition before and after sterilization are stable and tend to be neutral, the content of related substances and clinical irritation are low, and the argatroban drug composition is safe in use.

The invention relates to an injection preparation which uses argatroban as an active ingredient. It takes the single optical isomer of argatroban or its salt and hydrate as the medicinal active ingredient, adds some specific types and proportions of excipients, and prepares and develops it for intravenous injection according to the technical means described in this patent. preparations. Dosage forms include powder injection, small-volume injection or large-volume injection.

The invention discloses a synthesis method of argatroban .The method includes the step of making a compound II of a structure shown in the formula II make contact with and react with a hydrogen donor under the catalytic transfer hydrogenation conditions through the catalyst to obtain an argatroban rough product, wherein the hydrogen donor is formic acid or formate, and the formula II can be seen in the description .By means of the method, formic acid or formate serves as the hydrogen donor, the compound II is subjected to hydrogenation and reduction to obtain argatroban .By means of the method, in the hydrogenation and reduction process of the compound II, catalytic transfer hydrogenation reaction replaces catalytic hydrogenation reaction, operation steps are simplified, the problems on the aspects of technology and safety caused by hydrogen application are solved, reaction dangerousness is reduced, reaction conditions are mild and easy to control, and the method is more suitable for industrial application and production of argatroban.

The invention provides a method for analyzing N-nitrosodimethylamine and N-nitrosodiethylamine in an argatroban bulk drug or preparation, which adopts an ultra-high performance liquid chromatography (UPLC) and mass spectrometry combined method, and comprises the following steps: (1) preparing a test solution and a reference solution: dissolving a sample to be detected by using methanol as a solvent to prepare the test solution; dissolving standard substances of N-nitrosodimethylamine and N-nitrosodiethylamine by taking methanol as a solvent to prepare a reference substance solution; (2) taking the test solution and the reference substance solution, respectively injecting samples, detecting by using an ultra-high performance liquid chromatography-mass spectrometer, and recording a chromatogram map; and calculating the contents of N-nitrosodimethylamine and N-nitrosodiethylamine according to an external standard method. According to the liquid chromatography-mass spectrometry method provided by the invention, the sample treatment process is simple to operate, the sensitivity is high, the detection result is accurate, the stability is good, and the method can be used for quality control of argatroban bulk drugs or preparations.

The invention relates to a novel crystal form of argatroban and a preparation method thereof. The novel crystal form has characteristic peaks at 4.3+/-0.1, 7.4+/-0.1, 8.5+/-0.1, 8.8+/-0.1, 10.4+/-0.1, 10.7+/-0.1, 17.2+/-0.1, 17.9+/-0.1, 20.3+/-0.1, 22.5+/-0.1, 27.8+/-0.1 and the like by diffraction angle 2theta. The preparation method comprises the following steps: dissolving an argatroban coarse product in a mixed solvent of ethanol and water to prepare argatroban liquor; heating to 40-75 DEG C, and stirring, dissolving and clarifying; then, cooling and recrystallizing, filtering, vacuum drying to obtain the novel crystal form of argatroban. The product is uniformly paved in an opened culture dish, wherein the thickness of a sample is less than 5mm and the sample is hermetically placed in a drier at 50-80 DEG C, X-Ray Diffraction detections are carried out on samples respectively in 30 days and 60 days, the results are compared with the result at the 0th day, and the result shows that the novel crystal form of argatroban does not changed and is good in stability.

The invention discloses a 21 (R) argatroban intravenous injection containing at least one acid as a solubiliser. The intravenous injection is characterized in that at least one acid is utilized for improving the dissolvability of 21 (R) argatroban; at least one buffering agent is utilized for maintaining pH; and at least one penetration regulator is utilized for enhancing transfusion characteristics. A test result shows that the intravenous injection can avoid effectively hydrolysis and other chemical reactions, can be stored stably under light and heat conditions, and can be preserved at room temperature for at least 24 month.

The invention discloses an anticoagulant and metal-organic framework compound dual-modified in-vitro blood circulation pipeline coating and a preparation method thereof. The anticoagulant of the coating is selected from heparin, hirudin, citric acid or argatroban, and the metal-organic framework compound in the coating is MOF-Ag or MOF-Cu; the coating is obtained by fixing the metal-organic framework compound on the inner wall of an in-vitro blood circulation pipeline through dopamine and then fixing the anticoagulant on a dopamine layer with the metal-organic framework compound in a chemical grafting mode. The coating is high in stability, can improve blood compatibility and has excellent anticoagulation and antibacterial effects; and the in-vitro blood circulation pipeline with the coating can be applied to conventional hemodialysis, blood adsorption and continuous blood purification treatment.